FDA shows generic lamotrigine extended-release tablets are bioequivalent to innovator drug in fully replicated crossover bioequivalence study

FDA shows generic lamotrigine extended-release tablets are bioequivalent to innovator drug in fully replicated crossover bioequivalence study

Source: FDA Center for Drug Evaluation and Research - What's New - July 26, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news